Marc Tessier-Lavigne

US Patent:

6623738, Sep 23, 2003

Filed:

Nov 12, 1999

Appl. No.:

09/439711

Inventors:

Marc Tessier-Lavigne - San Francisco CA
Zhigang He - San Francisco CA
Hang Chen - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241391, 4241411, 4241481, 4241541, 4241721, 4241451, 435 71, 435332, 5303879

Abstract:

The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human cells. The invention provides isolated SR hybridization probes and primers, capable of specifically hybridizing with the disclosed SR genes. SR-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

US Patent:

6670451, Dec 30, 2003

Filed:

Oct 29, 2001

Appl. No.:

10/033174

Inventors:

Marc Tessier-Lavigne - San Mateo CA
Tito Serafini - San Francisco CA
Timothy Kennedy - San Francisco CA
Marysia Placzek - London, GB
Thomas Jessell - New York NY
Jane Dodd - New York NY

Assignee:

The Regents of the University of California - Oakland CA
Columbia University - New York NY

International Classification:

C07K 100

US Classification:

530350, 530395, 530399

Abstract:

Netrin proteins, nucleic acids which encode netrin proteins and hybridization reagents, probes and primers capable of hybridizing with netrin genes and methods for screening chemical libraries for lead compounds for pharmacological agents are provided.

US Patent:

6861228, Mar 1, 2005

Filed:

Nov 6, 2002

Appl. No.:

10/289776

Inventors:

Corey S. Goodman - Berkeley CA, US
Thomas Kidd - Berkeley CA, US
Katja Brose - San Francisco CA, US
Marc Tessier-Lavigne - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N033/53
A61K039/395
C07K016/18

US Classification:

435 71, 4241391, 5303871, 5303879

Abstract:

Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.

US Patent:

7919588, Apr 5, 2011

Filed:

May 1, 2008

Appl. No.:

12/151062

Inventors:

Marc Tessier-Lavigne - San Francisco CA, US
E. David Leonardo - San Francisco CA, US
Lindsay Hinck - San Francisco CA, US
Masayuki Masu - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 33/53
C07K 14/435

US Classification:

530350, 435 691, 4353201, 435325, 435 71, 514 11

Abstract:

The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host cells from the disclosed vertebrate UNC-5 encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed vertebrate unc-5 gene, vertebrate UNC-5-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

US Patent:

7943329, May 17, 2011

Filed:

Nov 9, 2007

Appl. No.:

11/983775

Inventors:

Jasvinder Atwal - San Carlos CA, US
Marc Tessier-Lavigne - Woodside CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

G01N 33/567

US Classification:

435 721, 435 71

Abstract:

The present invention provides methods and compositions related to CNS function and diseases.

US Patent:

7960125, Jun 14, 2011

Filed:

Sep 25, 2008

Appl. No.:

12/238288

Inventors:

David B. Lewis - Stanford CA, US
Christopher Haines - Menlo Park CA, US
Thierry Giffon - Mountain View CA, US
Xiaowei Lu - Charlottesville VA, US
Marc Tessier-Lavigne - South San Francisco CA, US
Douglas T. Ross - Huntsville AL, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

G01N 33/53

US Classification:

435 71, 435 724

Abstract:

The invention provides methods of identifying naïve T cells by expression of PTK7.

US Patent:

8350010, Jan 8, 2013

Filed:

Jun 28, 2011

Appl. No.:

13/171289

Inventors:

Anan Chuntharapai - Colma CA, US
Gregory D. Plowman - San Carlos CA, US
Marc Tessier-Lavigne - Woodside CA, US
Yan Wu - Foster City CA, US
Weilan Ye - Foster City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K 16/18

US Classification:

5303881

Abstract:

The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

US Patent:

20030040046, Feb 27, 2003

Filed:

Aug 20, 2001

Appl. No.:

09/933261

Inventors:

Marc Tessier-Lavigne - San Francisco CA, US
E. Leonardo - San Francisco CA, US
Lindsay Hinck - San Francisco CA, US
Masayuki Masu - San Francisco CA, US

International Classification:

C07K014/705
G01N033/53
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/007100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host cells from the disclosed vertebrate UNC-5 encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed vertebrate unc-5 gene, vertebrate UNC-5-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.